Current Valuation
N/A
As of May 7, 2024
Total Funding Raised
$96.6M
Last Round
Later Stage VC

$49.4M

Last Funding
May 2024

Funding date

Capital Efficiency
N/A

Valuation / Funding

Funding History & Valuation Timeline
Complete history of all funding rounds and valuation milestones

No funding history available

Funding data has not been imported for this company yet

Valuation Analysis

Current Valuation Metrics

Memo Therapeutics is currently valued at N/A as of May 7, 2024. The company has raised a total of $96.6M in funding.

Investment Perspective

Memo Therapeutics's valuation reflects investor confidence in the company's market position, growth potential, and ability to execute on its business model. Private market valuations are determined by primary funding rounds and secondary market transactions, which take into account financial performance, market conditions, and growth prospects.

Track Memo Therapeutics Valuation Updates

Get notified when Memo Therapeutics raises new funding or valuation changes

What is Memo Therapeutics Worth in 2025?

As of 2025, Memo Therapeutics is valued at N/A, based on the company's Later Stage VC funding round in May 7, 2024. This valuation positions Memo Therapeutics as one of the leading private companies in the sector.

Memo Therapeutics Valuation History

Memo Therapeutics's funding history demonstrates steady growth and investor confidence.

How Memo Therapeutics Valuation is Determined

Private company valuations like Memo Therapeutics's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including:

  • Revenue growth and financial performance
  • Market opportunity and total addressable market (TAM)
  • Competitive positioning and market share
  • Management team strength and execution capability
  • Technology and intellectual property
  • Industry trends and investor sentiment

Memo Therapeutics Valuation FAQs

Is Memo Therapeutics profitable?

Memo Therapeutics has not publicly disclosed its profitability status. Many high-growth private companies prioritize market expansion and user growth over profitability in their early stages.

How does Memo Therapeutics's valuation compare to competitors?

Memo Therapeutics is valued at N/A, positioning it as a major player in the space. Secondary market pricing and private market transactions provide ongoing validation of this valuation.

When will Memo Therapeutics IPO?

Memo Therapeutics has not announced plans for an initial public offering. Until an IPO, investors can access Memo Therapeutics shares through secondary market platforms.